Ixabepilone

Alison Conlin; Monica Fornier; Clifford Hudis; Santwana Kar; Peter Kirkpatrick

doi:10.1038/nrd2469

journal article Dec 01, 2007

Ixabepilone

Alison Conlin Monica Fornier Clifford Hudis Santwana Kar Peter Kirkpatrick

Nature Reviews Drug Discovery Vol. 6 No. 12 pp. 953-954 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nrd2469

Topics

No keywords indexed for this article. Browse by subject →

References

15

[1]

Microtubules as a target for anticancer drugs

Mary Ann Jordan, Leslie Wilson

Nature Reviews Cancer 2004 10.1038/nrc1317

[2]

Cortes, J. & Baselga, J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 12, 271–280 (2007). 10.1634/theoncologist.12-3-271

[3]

Bollag, D. M. et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55, 2325–2333 (1995).

[4]

Lee, F. Y. et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 7, 1429–1437 (2001).

[5]

Food and Drug Administration. FDA labelling information [ online ], (2007).

[6]

Vahdat, L. T. et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. J. Clin. Oncol. 25, 18S (2007). 10.1200/jco.2007.25.18_suppl.1006

[7]

Perez, E. A. et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25, 3407–3414 (2007). 10.1200/jco.2006.09.3849

[8]

Sledge, G. W. Jr et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J. Clin. Oncol. 21, 588–592 (2003). 10.1200/jco.2003.08.013

[9]

Fumoleau, P. et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur. J. Cancer 40, 536–542 (2004). 10.1016/j.ejca.2003.11.007

[10]

Reichardt, P. et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann. Oncol. 14, 1227–1233 (2003). 10.1093/annonc/mdg346

[11]

Blum, J. L. et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17, 485–493 (1999). 10.1200/jco.1999.17.2.485

[12]

Wist, E. A. et al. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol. 43, 186–189 (2004). 10.1080/02841860310023165

[13]

Pivot, X. et al. Ixabepilone in patients (pts) with metastatic breast cancer (MBC) that is resistant to an anthracycline, a taxane and capecitabine. Ann. Oncol. 17, ix70 (2006).

[14]

Baselga, J. et al. Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res. Treat 94, S31 (2005).

[15]

IMS MIDAS Quantum (2007).

Metrics

60

Citations

15

References

Details

Published: Dec 01, 2007
Vol/Issue: 6(12)
Pages: 953-954
License: View

Authors

Cite This Article

Alison Conlin, Monica Fornier, Clifford Hudis, et al. (2007). Ixabepilone. Nature Reviews Drug Discovery, 6(12), 953-954. https://doi.org/10.1038/nrd2469

Ixabepilone

You May Also Like